Olumiant (Baricitinib) — Patient Information (UK)

Olumiant contains baricitinib, a medicine used to reduce inflammation and help manage certain immune-mediated conditions. This page explains what Olumiant is, how it works, how it is typically used, and what to know for safety in everyday life in the United Kingdom.

Always follow the advice given by your healthcare professional. Information here is intended to be patient-friendly and practical, not a substitute for individual medical care.

Basic product information

• Medicine name: Olumiant
• Active ingredient: Baricitinib
• Medicinal form: Tablets (strengths may vary by prescription and availability)
• Class: Janus kinase (JAK) inhibitor
• How it is used: Usually taken once daily (exact regimen depends on the condition and individual factors)
• Manufacturer/brand: Branded as Olumiant

What is baricitinib and how does it work?

Baricitinib is a JAK inhibitor. The immune system communicates through chemical signals called cytokines. Many cytokines signal through enzymes known as Janus kinases (JAKs). By blocking these pathways, baricitinib can reduce inflammatory signalling.

Mechanism of action (simple explanation)

• In certain inflammatory diseases, the immune system becomes overly active.
• That overactivity is driven by cytokine signalling.
• Baricitinib inhibits JAK pathways involved in that signalling.
• Result: less inflammation and disease activity.

Pharmacokinetics (how the body handles the medicine)

“Pharmacokinetics” describes how a medicine is absorbed, distributed, metabolised, and eliminated. Understanding these basics helps explain timing and food effects.

What is Olumiant used for?

In the UK, Olumiant is used for immune-mediated inflammatory conditions where JAK inhibition may help control disease activity. The exact approved uses can depend on current UK regulatory authorisations and clinical guidance.

Common indications (by condition)

• Rheumatoid arthritis (RA): to reduce symptoms and improve physical function in adults, often when other treatments are insufficient.
• Atopic dermatitis (eczema): in adults and/or adolescents depending on the current licensed age group and treatment criteria.
• Alopecia areata: in appropriate adults and/or adolescents, when suitable.

The suitability of baricitinib for you depends on factors such as diagnosis, severity, prior treatments, risk profile (including infections and blood clot risk), kidney function, and overall health.

Typical timing and how to take Olumiant

For many patients, Olumiant is taken once daily. It may be taken at any time of day as long as you are consistent. Your healthcare team will specify your exact dose and schedule.

Practical daily routine

• Choose a consistent time: e.g., morning or evening.
• With or without food: You can generally take it without special timing restrictions around meals.
• Swallow whole: do not crush or split tablets unless instructed otherwise.
• Use reminders: phone alarms can reduce missed doses.

If you miss a dose

If you miss a dose, take it when you remember unless it is close to your next dose. Do not take two doses at the same time to make up for the missed one. If you are unsure, consult your healthcare provider or pharmacist.

Food interactions and alcohol

Food interactions

Baricitinib can generally be taken with or without food. Food is not usually expected to significantly prevent absorption. However, individual product guidance may include details for fasting vs. fed states; follow your medicine label and professional advice.

If you experience stomach upset when taking the tablet, consider taking it with food and stay consistent. Always discuss persistent gastrointestinal symptoms with a clinician.

Alcohol

There is no simple “universal” rule that everyone must avoid alcohol completely on baricitinib. However, because baricitinib can affect liver-related pathways in some people and because infections may be more important to avoid, it is sensible to keep alcohol moderate and avoid heavy drinking.

• Consider limiting alcohol intake.
• Seek medical advice if you have liver disease, hepatitis, or abnormal liver tests.
• Contact a clinician if you develop signs of infection or feel unwell after starting treatment.

Medication interactions (important)

Baricitinib can interact with other medicines, particularly those affecting immune function, kidney handling, and certain metabolic pathways. Some interactions may increase side effects; others may reduce effectiveness.

Common interaction categories to discuss with your pharmacist

• Other immunosuppressants: combining with certain immune-modulating therapies may increase infection risk.
• JAK inhibitors or biologics: generally avoid combining with another JAK inhibitor unless specifically advised.
• Strong inhibitors or inducers of relevant enzymes/transporters: may change baricitinib blood levels.
• Medicines affecting the kidneys: if kidney function changes, baricitinib exposure may change too.
• Live vaccines: may not be recommended during treatment with immune-modulating medicines. Discuss vaccination plans early.

Always tell your healthcare provider

Before starting Olumiant, share a full list of medicines and supplements you use, including:

• prescription medicines
• over-the-counter products (e.g., pain relief, cold remedies)
• herbal supplements
• recent antibiotics or antifungal medicines
• any recent infections

Dosing (how much is typical?)

Dosing is individual. The dose depends on your condition, age, kidney function, and safety considerations. Your clinician will decide the correct starting dose and may adjust it based on blood test results and response.

General dosing principles

• One tablet per day is common for many indications.
• Kidney function matters: people with reduced kidney function may need a lower dose.
• Blood tests may guide dosing: safety monitoring includes full blood counts and other labs.
• Review response: treatment effectiveness may be assessed after several weeks, and longer-term decisions follow.

Because strengths and dosing schedules can vary, always check your personal medication label for your exact dose and schedule.

Indications and how Olumiant fits into treatment

Olumiant is usually considered when the immune-mediated disease is active and other therapies are insufficient, not suitable, or have not achieved adequate control. Your clinician will weigh benefits against risks such as infection.

What “works” may look like

• Reduced symptoms: e.g., less joint pain and swelling in RA, less itch and inflammation in eczema, reduced hair loss in alopecia areata.
• Improved daily function: more comfortable movement, improved skin condition, or improved quality of life.
• Better disease control: fewer flare-ups over time.

How soon might it help?

Response varies between people and between conditions. Some people notice improvement within weeks, while others may take longer. If you are not seeing progress, your clinician may reassess treatment strategy.

• Early changes: symptoms may start to ease within the first few weeks.
• Ongoing assessment: longer-term improvement is often evaluated over subsequent months.
• Consistency is key: take the tablet daily as instructed.

Safety profile: important risks and who needs extra caution

Like all medicines, Olumiant can cause side effects. Many people tolerate treatment well, but baricitinib can increase susceptibility to infections and can have effects on blood counts and certain lab markers.

Common side effects (may include)

• headache
• upper respiratory tract infections (such as a cold)
• nausea or stomach discomfort
• increased cholesterol levels (detected on blood tests)
• changes in blood counts (as seen on routine monitoring)

Serious risks (seek urgent advice if you suspect)

• Serious infections: fever, chills, shortness of breath, worsening cough, painful urination, or symptoms that do not improve.
• Blood clots: sudden breathlessness, chest pain, leg swelling/pain (urgent medical attention is needed).
• Changes in blood counts: extreme tiredness, unusual bruising or bleeding, persistent sore throat or mouth ulcers.
• Allergic reactions: swelling of face/lips, rash, or breathing difficulty.

The overall risk-benefit balance depends on your individual risk factors and the condition being treated. Your clinician will discuss monitoring plans and how to respond to symptoms.

Who needs extra caution?

• history of recurrent or serious infections
• known kidney impairment
• older age or multiple cardiovascular risk factors
• history of blood clots or risk factors for clotting
• active tuberculosis or hepatitis status (screening may be performed)
• current or recent use of other immune-modulating medicines

Practical use tips (day-to-day)

Before you start

• Infection check: tell your clinician about any ongoing infections or recent antibiotics.
• TB and hepatitis screening: many immune medicines require screening before starting.
• Baseline blood tests: full blood counts and other safety labs are typically used.
• Medication review: bring a list of all your medicines and supplements.

During treatment

• Don’t delay seeking help for infections: contact your healthcare team promptly if you feel unwell.
• Attend routine blood tests: monitoring supports safe ongoing use.
• Maintain infection-prevention habits: hand hygiene and avoiding close contact with people who have contagious illnesses.
• Know what “normal” feels like: track symptoms such as fever, unusual bruising, or breathlessness.

Handling interruptions

If you develop a significant infection or your clinician advises a temporary stop, follow their instructions. Do not restart without guidance.

Alternative options to consider (discuss with your clinician)

Depending on the condition you are treating, alternatives may include other disease-modifying therapies and anti-inflammatory approaches. The best choice depends on your diagnosis, severity, previous treatments, and safety profile.

Possible alternative categories

• Conventional disease-modifying drugs (for some conditions, such as RA)
• Biologic medicines (targeting specific immune pathways)
• Other JAK inhibitors (when appropriate)
• Topical or targeted therapies (particularly for skin conditions, depending on severity)
• Supportive and symptom-relief measures alongside disease control

If you are considering switching, your clinician will plan a safe transition and may require monitoring to reduce risks.

Market and legal context in the UK (overview)

Olumiant is a medicine authorised and regulated in the United Kingdom under the relevant medicines framework. As with all medicines, it must be used according to current UK regulatory approvals and professional guidance.

Like other medicines that affect the immune system, baricitinib use in the UK is guided by national and specialty recommendations, including:

• safety monitoring requirements
• screening for infections such as tuberculosis and hepatitis where appropriate
• review of cardiovascular and clot risk factors
• consideration of vaccination status

Recent guidance (what matters for patients)

Guidance for JAK inhibitors may evolve as new safety data and clinical evidence become available. In the UK, healthcare professionals follow updated summaries and safety communications relevant to baricitinib.

While the exact details can vary over time, patient-relevant themes commonly include:

• regular blood monitoring (full blood count and other parameters)
• ongoing infection awareness and early reporting
• individual assessment of clot risk and cardiovascular factors
• review of other medications to avoid unsafe combinations

Your clinician can explain how these updates apply to your personal situation.

Delivery and availability (UK online pharmacy)

We aim to keep Olumiant tablets available, subject to stock levels and manufacturer supply. Availability can vary by tablet strength and packaging.

• Dispatch: orders are typically dispatched on working days, subject to payment and stock confirmation.
• Delivery times: delivery estimates are provided at checkout and may depend on your location in the UK.
• Packaging: medicines are supplied in secure packaging to protect privacy and integrity.
• Cold chain: baricitinib tablets do not generally require special temperature-controlled shipping.
• Prescription documentation: follow UK pharmacy requirements and the documents requested at order completion.

If a specific strength is temporarily out of stock, you may be offered alternatives or notified when it becomes available. Where relevant, you can also contact our customer team to ask about expected restock dates.

Storage and handling

• Store at reasonable room temperature, away from excessive heat and direct sunlight.
• Keep tablets in their original packaging until use.
• Keep out of sight and reach of children.
• Do not use tablets after the expiry date on the pack.

FAQ

1) What is Olumiant used for?

Olumiant (baricitinib) is used for immune-mediated inflammatory conditions such as rheumatoid arthritis and other specified skin/hair conditions, depending on the current UK licensed indications and your individual circumstances.

2) How do I take Olumiant?

Usually once daily. Take the tablet at the same time each day. You can generally take it with or without food. Swallow whole with water.

3) Will food affect how it works?

Food is generally not expected to significantly reduce absorption. You can usually take Olumiant with or without meals.

4) Can I drink alcohol while taking baricitinib?

Moderate alcohol is usually possible for many people, but heavy drinking may increase strain on the body and should be avoided. If you have liver problems or are concerned, ask your clinician or pharmacist for personalised advice.

5) What should I do if I develop an infection?

Contact your healthcare team promptly if you develop fever, chills, worsening cough, painful urination, or symptoms that suggest an infection. Early assessment is important because immune-modulating medicines can increase infection risk.

6) What routine monitoring will I need?

Monitoring commonly includes blood tests (such as full blood counts and other safety labs) and clinical review. Your doctor will set a schedule.

7) Are there vaccinations I should avoid?

Live vaccines may not be recommended during treatment with immune-modulating medicines. If you need vaccinations, discuss timing with your clinician ahead of time.

8) What are the most important side effects?

Common effects may include infections and headache. Serious risks can include serious infection, blood clots, and changes in blood counts. Seek urgent help if you experience severe symptoms such as breathlessness, chest pain, high fever, or signs of allergic reaction.

9) Can I take other medicines at the same time?

Some medicines can interact with baricitinib or increase side effect risk—particularly other immunosuppressants or medicines that affect drug processing. Tell your pharmacist about all medicines and supplements you take.

10) What if I miss a dose?

Take it when you remember unless it is close to the next dose. Do not take a double dose to make up for the missed tablet.

11) Are there alternatives to Olumiant?

Yes. Alternatives may include other disease-modifying therapies, biologics, different JAK inhibitors, or condition-specific treatments. Your healthcare professional can advise what fits your diagnosis and risk profile.

Need more help?

If you have questions about baricitinib, your specific strength, suitability, or safe use alongside your current medications, please speak to a healthcare professional. Our team can also help with general product availability information for the UK.